Justin B. Klee is CEO at Amylyx Pharmaceuticals, Inc. (AMLX). They have made 14 open-market trades across 1 company since 2023, most recently 2026-09-10.
CIK 0001898314
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AMLX | 3,613,056 | $106.3M |
Shares reported on the most recent Form 4, priced at the 2026-09-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AMLX | SELL | 2026-09-10 | 2026-09-14 | $32.18 | $980K | -8.7% | -18.2% | — |
| AMLX | SELL | 2026-03-02 | 2026-03-04 | $14.47 | $424K | -3.3% | +6.3% | -10.7% |
| AMLX | SELL | 2026-02-02 | 2026-02-04 | $14.69 | $228K | +2.7% | +0.7% | +19.4% |
| AMLX | SELL | 2026-01-15 | 2026-01-20 | $13.59 | $1.9M | -12.5% | -14.2% | +7.5% |
| AMLX | SELL | 2026-01-06 | 2026-01-08 | $11.09 | $86K | +42.4% | +19.7% | +42.6% |
| AMLX | SELL | 2025-09-30 | 2025-10-02 | $14.37 | $859K | +4.6% | +0.3% | -10.9% |
| AMLX | SELL | 2025-03-31 | 2025-04-02 | $3.46 | $149K | +10.5% | +50.7% | +81.6% |
| AMLX | SELL | 2025-03-03 | 2025-03-05 | $3.15 | $14K | +15.7% | +5.9% | +58.0% |
| AMLX | SELL | 2025-02-03 | 2025-02-05 | $3.47 | $41K | -3.8% | +4.6% | +25.7% |
| AMLX | SELL | 2025-01-06 | 2025-01-08 | $4.04 | $30K | -6.5% | +2.2% | -11.0% |
| AMLX | SELL | 2024-09-30 | 2024-10-02 | $3.20 | $119K | +18.9% | +87.4% | +25.6% |
| AMLX | SELL | 2024-03-05 | 2024-03-07 | $18.73 | $155K | -2.0% | -10.0% | -41.1% |
| AMLX | SELL | 2024-01-09 | 2024-01-11 | $16.33 | $191K | -10.6% | +1.1% | -84.7% |
| AMLX | SELL | 2023-03-16 | 2023-03-20 | $31.86 | $6.4M | -15.1% | -3.8% | -25.2% |
| AMLX | SELL · 10b5-1 | 2023-01-06 | 2023-01-10 | $36.30 | $217K | +5.3% | -6.6% | -19.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.